Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.4 USD | -0.92% | +4.04% | +39.20% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- The company has insufficient levels of profitability.
- With an expected P/E ratio at 93.08 and 63.68 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+39.20% | 3.57B | C+ | ||
-17.89% | 8.25B | B+ | ||
-39.11% | 2.46B | B- | ||
-8.06% | 2.46B | - | ||
-7.35% | 2.38B | B- | ||
-12.61% | 1.81B | C- | ||
-19.01% | 1.55B | A- | ||
-40.66% | 1.21B | C+ | ||
+7.56% | 1.11B | B+ | ||
-15.34% | 1.03B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RDNT Stock
- Ratings RadNet, Inc.